Pasar al contenido principal

Identification of new therapeutic targets in kidney disease

RYC2018-024461-I

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Incorporación
Convocatoria Ramón y Cajal
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NIK Is a Mediator of Inflammation and Intimal Hyperplasia in Endothelial Denudation-Induced Vascular Injury

  • Baeza, Ciro
  • Ribagorda, Marta
  • Maya-López, Carla
  • Fresno, Manuel
  • Sánchez-Díaz, Tania
  • Pintor-Chocano, Aránzazu
  • Sanz, Ana Belén
  • Carrasco, Susana
  • Ortiz, Alberto
  • Sánchez-Niño, Maria D.
Neointimal hyperplasia is the main cause of vascular graft failure in the medium term. NFκB is a key mediator of inflammation that is activated during neointimal hyperplasia following endothelial injury. However, the molecular mechanisms involved in NFκB activation are poorly understood. NFκB may be activated through canonical (transient) and non-canonical (persistent) pathways. NFκB-inducing kinase (NIK, MAP3K14) is the upstream kinase of the non-canonical pathway. We have now explored the impact of NIK deficiency on neointimal hyperplasia following guidewire-induced endothelial cell injury and on local inflammation by comparing NIK activity–deficient alymphoplasia mice (NIKaly/aly) with control wild-type (NIK+/+) mice. Guidewire-induced endothelial cell injury caused neointimal hyperplasia and luminal stenosis and upregulated the local expression of NIK and the NFκB target chemokines monocyte chemoattractant protein-1 (MCP-1/CCL2) and chemokine ligand 5 (RANTES/CCL5). Immunohistochemistry disclosed the infiltration of the media and intima by F4/80 positive macrophages. The intima/media ratio and percentage of stenosis were milder in the NIKaly/aly than in the NIK+/+ mice. Additionally, the gene expression for MCP-1 and RANTES was lower and F4/80+ cell infiltration was milder in the NIKaly/aly than in the NIK+/+ mice. Finally, circulating MCP-1 levels were lower in the NIKaly/aly than in the NIK+/+ mice, reflecting milder systemic inflammation. In conclusion, NIK is a driver of vascular wall inflammation and stenosis following guidewire-induced endothelial cell injury. NIK targeting may be a novel therapeutic approach to limit arterial stenosis following endothelial cell injury., We gratefully acknowledge the Agencia Estatal de Investigación (AEI) MICIN (CNS2022-135937), Sociedad Española de Nefrología, Sociedad Madrileña de Nefrología (SOMANE), FRIAT, Comunidad de Madrid en Biomedicina P2022/BMD-7223, CIFRA_COR-CM. Instituto de Salud Carlos III (ISCIII) FIS/Fondos FEDER (PI22/00050, PI21/00251, ERA-PerMed-JTC2022 (SPAREKID AC22/00027), RICORS program to RICORS2040 (RD21/0005/0001) funded by European Union—NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia (MRR) and SPACKDc PMP21/00109, FEDER funds, COST Action PERMEDIK CA21165, supported by COST (European Cooperation in Science and Technology); PREVENTCKD Consortium. Project ID: 101101220 Program: EU4H DG/Agency: HADEA and from “MICIN” (SAF2016-75988-R and PID2022-137487OB-I00) and “Comunidad de Madrid” (S2017/BMD-3671. INFLAMUNE-CM; FEDER) to MF. MDSN was supported by MICINN Ramon y Cajal program RYC2018-024461-I., Peer reviewed
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Identification and study of new NF‐κB‐inducing kinase ligands derived from the imidazolone scaffold

  • Maqueda Zelaya, Francisco|||0000-0002-9962-159X
  • Valiño Rivas, Lara
  • Milián López, Ana|||0000-0001-6101-077X
  • Gutiérrez Hernández, Sara
  • Aceña Bonilla, José Luis|||0000-0002-1777-8199
  • García Marin, Javier|||0000-0002-5883-4783
  • Sánchez Niño, María Dolores
  • Vaquero López, Juan José|||0000-0002-3820-9673
  • Ortiz, Alberto
Chronic kidney disease (CKD) is a growing health concern, projected to be a major cause of death by 2040, due to an increasing risk of acute kidney injury (AKI). Systems biology‐ derived data suggest that the unmet need for an orally available drug to treat AKI and improve CKD outcomes may be addressed by targeting kidney inflammation and, specifically, nuclear factor kappaB‐inducing kinase (NIK), a key signaling molecule that activates the noncanonical nuclear factor kappaB (NF‐kappaB) pathway. We have prepared and identified a small family of imidazolone derivatives that bind NIK and inhibit the noncanonical NF‐kappaB activation pathway. The introduction of heterocyclic substituents in position 2 of the imidazolone core provides compounds with affinity against human NIK. Three candidates, with best affinity profile, were tested in phenotypic experiments of noncanonical NF‐kappaB activation, confirming that the derivative bearing the 4‐pyridyl ring can inhibit the processing of NFkappaB p100 to NFkB2 p52, which is NIK‐dependent in cultured kidney tubular cells. Finally, exhaustive docking calculations combined with molecular dynamics studies led us to propose a theoretical binding mode and rationalize affinity measures, in which the aminopyridine motif is a key anchoring point to the hinge region thanks to several hydrogen bonds and the interaction of heterocyclic rings in position 2 with Ser476 and Lys482. Our result will pave the way for the development of potential drug candidates targeting NIK in the context of CKD., Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III, Comunidad de Madrid, Universidad de Alcalá, European Union